Sterling Pharma Solutions Acquires US API Facility

Sterling Pharma Solutions, a global contract development and manufacturing organization, has announced, in a Sept. 30, 2020 press release, that it has acquired Alcami’s API facility in Germantown, WI.

The newly acquired facility will boost Sterling’s presence in the United States and will provide further capacity for the company’s customer API development and manufacturing projects, particularly those projects with complex and hazardous requirements. The Germantown facility comprises current good manufacturing practice development, scale-up, and manufacturing facilities, and has specialist expertise in handling technologies, such as plant-scale hydrogenation and cryogenic reactions.

“We’re delighted to announce our acquisition of the Germantown facility in the US. This is the latest step of our strategic growth plans and will ensure we continue to provide a strong transatlantic API presence to support our customers,” said Kevin Cook, CEO of Sterling Pharma Solutions, in the press release. “The US market continues to be a key growth area for us. In addition to bolstering our API clinical and commercial manufacturing the Germantown facility has extensive expertise in handling high potency APIs, which will be a valuable addition to our organization.”

“We want to thank the Germantown leadership team and employees for their dedication to the business and wish them success in the future,” added Walt Kaczmarek, CEO of Alcami, in the press release. “Alcami has over 40 years of experience providing comprehensive drug product manufacturing and analytical testing services. This transaction continues our strategy to focus investments on our core service offerings.”

Source: Sterling Pharma Solutions​